trending Market Intelligence /marketintelligence/en/news-insights/trending/yjyixso3h7l4mo20c9t6dq2 content esgSubNav
In This List

Adaptimmune secures $100M funding from private equity firms


Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap


Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future


Street Talk | Episode 99 - Higher rates punish bond portfolios, weigh on bank M&A


Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Adaptimmune secures $100M funding from private equity firms

Adaptimmune Therapeutics PLC said it had attracted a $100 million investment from a handful of private equity firms.

Adaptimmune entered an agreement with Matrix Capital Management Co. LP, New Enterprise Associates 16 LP, New Enterprise Associates 14 LP and Syncona Ltd. The firms will buy $100 million worth of the U.K.-based biopharmaceutical company's American depositary shares at $10 each.

The offering is expected to close Sept. 7, subject to customary closing conditions.

Adaptimmune said net proceeds will be used for the clinical development of its wholly owned pipeline of SPEAR T-cell candidates for treating multiple types of cancer and for other general corporate purposes.

In July, GlaxoSmithKline PLC acquired one of the cell therapy programs from Adaptimmune for about $27.5 million.

"This financing strengthens our balance sheet and extends our runway through to late 2020," Adaptimmune CEO James Noble said in a statement.